title: Dyskinesias assessment in Phase II studies.
authors.affiliation: Centre d'Investigation Clinique-INSERM U 289, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Damier
authors.forename: C
authors.initials: C
authors.lastname: Jaillon
authors.forename: I
authors.initials: I
authors.lastname: Clavier
authors.forename: I
authors.initials: I
authors.lastname: Arnulf
authors.forename: A M
authors.initials: AM
authors.lastname: Bonnet
authors.forename: B P
authors.initials: BP
authors.lastname: Bejjani
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
mesh_terms: D001692:Biological Transport / Q000502:physiology; D001921:Brain / Q000378:metabolism; D002985:Clinical Protocols; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis* / Q000209:etiology*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity
chemical_list: D018491:Dopamine Agonists; D007980:Levodopa; D004298:Dopamine